-
Je něco špatně v tomto záznamu ?
Antimycobacterial pyridine carboxamides: From design to in vivo activity
DE. Nawrot, G. Bouz, O. Janďourek, K. Konečná, P. Paterová, P. Bárta, M. Novák, R. Kučera, J. Zemanová, M. Forbak, J. Korduláková, O. Pavliš, P. Kubíčková, M. Doležal, J. Zitko
Jazyk angličtina Země Francie
Typ dokumentu časopisecké články
Odkazy
PubMed
37423128
DOI
10.1016/j.ejmech.2023.115617
Knihovny.cz E-zdroje
- MeSH
- antituberkulotika chemie MeSH
- isoniazid farmakologie MeSH
- kyselina aminosalicylová * farmakologie MeSH
- lidé MeSH
- methionin MeSH
- mikrobiální testy citlivosti MeSH
- Mycobacterium tuberculosis * MeSH
- myši MeSH
- tuberkulóza * farmakoterapie mikrobiologie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
Tuberculosis is the number one killer of infectious diseases caused by a single microbe, namely Mycobacterium tuberculosis (Mtb). The success rate of curing this infection is decreasing due to emerging antimicrobial resistance. Therefore, novel treatments are urgently needed. As an attempt to develop new antituberculars effective against both drugs-sensitive and drug-resistant Mtb, we report the synthesis of a novel series inspired by combining fragments from the first-line agents isoniazid and pyrazinamide (series I) and isoniazid with the second-line agent 4-aminosalicylic acid (series II). We identified compound 10c from series II with selective, potent in vitro antimycobacterial activity against both drug-sensitive and drug-resistant Mtb H37Rv strains with no in vitro or in vivo cytotoxicity. In the murine model of tuberculosis, compound 10c caused a statistically significant decrease in colony-forming units (CFU) in spleen. Despite having a 4-aminosalicylic acid fragment in its structure, biochemical studies showed that compound 10c does not directly affect the folate pathway but rather methionine metabolism. In silico simulations indicated the possibility of binding to mycobacterial methionine-tRNA synthetase. Metabolic study in human liver microsomes revealed that compound 10c does not have any known toxic metabolites and has a half-life of 630 min, overcoming the main drawbacks of isoniazid (toxic metabolites) and 4-aminosalicylic acid (short half-life).
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23016086
- 003
- CZ-PrNML
- 005
- 20240522135216.0
- 007
- ta
- 008
- 231013e20230630fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejmech.2023.115617 $2 doi
- 035 __
- $a (PubMed)37423128
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Nawrot, Daria Elżbieta $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 50005, Hradec Králové, Czech Republic. Electronic address: nawrotd@faf.cuni.cz
- 245 10
- $a Antimycobacterial pyridine carboxamides: From design to in vivo activity / $c DE. Nawrot, G. Bouz, O. Janďourek, K. Konečná, P. Paterová, P. Bárta, M. Novák, R. Kučera, J. Zemanová, M. Forbak, J. Korduláková, O. Pavliš, P. Kubíčková, M. Doležal, J. Zitko
- 520 9_
- $a Tuberculosis is the number one killer of infectious diseases caused by a single microbe, namely Mycobacterium tuberculosis (Mtb). The success rate of curing this infection is decreasing due to emerging antimicrobial resistance. Therefore, novel treatments are urgently needed. As an attempt to develop new antituberculars effective against both drugs-sensitive and drug-resistant Mtb, we report the synthesis of a novel series inspired by combining fragments from the first-line agents isoniazid and pyrazinamide (series I) and isoniazid with the second-line agent 4-aminosalicylic acid (series II). We identified compound 10c from series II with selective, potent in vitro antimycobacterial activity against both drug-sensitive and drug-resistant Mtb H37Rv strains with no in vitro or in vivo cytotoxicity. In the murine model of tuberculosis, compound 10c caused a statistically significant decrease in colony-forming units (CFU) in spleen. Despite having a 4-aminosalicylic acid fragment in its structure, biochemical studies showed that compound 10c does not directly affect the folate pathway but rather methionine metabolism. In silico simulations indicated the possibility of binding to mycobacterial methionine-tRNA synthetase. Metabolic study in human liver microsomes revealed that compound 10c does not have any known toxic metabolites and has a half-life of 630 min, overcoming the main drawbacks of isoniazid (toxic metabolites) and 4-aminosalicylic acid (short half-life).
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a isoniazid $x farmakologie $7 D007538
- 650 12
- $a kyselina aminosalicylová $x farmakologie $7 D010131
- 650 _2
- $a antituberkulotika $x chemie $7 D000995
- 650 12
- $a Mycobacterium tuberculosis $7 D009169
- 650 12
- $a tuberkulóza $x farmakoterapie $x mikrobiologie $7 D014376
- 650 _2
- $a methionin $7 D008715
- 650 _2
- $a mikrobiální testy citlivosti $7 D008826
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Bouz, Ghada $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 50005, Hradec Králové, Czech Republic. Electronic address: bouzg@faf.cuni.cz
- 700 1_
- $a Janďourek, Ondřej $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 50005, Hradec Králové, Czech Republic. Electronic address: jando6aa@faf.cuni.cz
- 700 1_
- $a Konečná, Klára $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 50005, Hradec Králové, Czech Republic. Electronic address: konecna@faf.cuni.cz
- 700 1_
- $a Paterová, Pavla $u Department of Clinical Microbiology, University Hospital, Sokolská 581, 500 05, Hradec, Králové, Czech Republic. Electronic address: pavla.paterova@fnhk.cz
- 700 1_
- $a Bárta, Pavel $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 50005, Hradec Králové, Czech Republic. Electronic address: bartp7aa@faf.cuni.cz
- 700 1_
- $a Novák, Martin $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 50005, Hradec Králové, Czech Republic; Biomedical Research Center, University Hospital Hradec Kralove, Sokolská 581, 50005, Hradec Králové, Czech Republic. Electronic address: martin.novak@fnhk.cz
- 700 1_
- $a Kučera, Radim $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 50005, Hradec Králové, Czech Republic. Electronic address: kucerar@faf.cuni.cz
- 700 1_
- $a Zemanová, Júlia $u Department of Biochemistry, Faculty of Natural Sciences, Comenius University in Bratislava, Mlynská Dolina, Ilkovičova 6, 84215, Bratislava, Slovakia. Electronic address: julia.zemanova@uniba.sk
- 700 1_
- $a Forbak, Martin $u Department of Biochemistry, Faculty of Natural Sciences, Comenius University in Bratislava, Mlynská Dolina, Ilkovičova 6, 84215, Bratislava, Slovakia. Electronic address: forbak1@uniba.sk
- 700 1_
- $a Korduláková, Jana $u Department of Biochemistry, Faculty of Natural Sciences, Comenius University in Bratislava, Mlynská Dolina, Ilkovičova 6, 84215, Bratislava, Slovakia. Electronic address: jana.kordulakova@uniba.sk
- 700 1_
- $a Pavliš, Oto $u Military Health Institute, Military Medical Agency, Tychonova 1, 160 01, Prague 6, Czech Republic. Electronic address: oto.pavlis@email.cz
- 700 1_
- $a Kubíčková, Pavla $u Military Health Institute, Military Medical Agency, Tychonova 1, 160 01, Prague 6, Czech Republic. Electronic address: pafcule@centrum.cz
- 700 1_
- $a Doležal, Martin, $d 1961- $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 50005, Hradec Králové, Czech Republic. Electronic address: dolezalm@faf.cuni.cz $7 jn19981000714
- 700 1_
- $a Zitko, Jan $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 50005, Hradec Králové, Czech Republic. Electronic address: jan.zitko@faf.cuni.cz
- 773 0_
- $w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 258 (20230630), s. 115617
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37423128 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20231013 $b ABA008
- 991 __
- $a 20240522135212 $b ABA008
- 999 __
- $a ok $b bmc $g 1999917 $s 1202448
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 258 $c - $d 115617 $e 20230630 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
- LZP __
- $a Pubmed-20231013